Literature DB >> 498421

A survey of the anthracycline derivatives in hematology.

C Jacquillat, M Weil, M F Auclerc, J Maral, G Schaison, M Boiron, J Bernard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 498421     DOI： 10.1007/bf00253106

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  16 in total

1.  Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation.

Authors:  N R Bachur; S L Gordon; M V Gee
Journal:  Mol Pharmacol       Date:  1977-09       Impact factor: 4.436

2.  [A NEW ANTIBIOTIC WITH CYTOSTATIC PROPERTIES: RUBIDOMYCIN].

Authors:  M DUBOST; P GANTER; R MARAL; L NINET; S PINNERT; J PREUDHOMME; G H WERNER
Journal:  C R Hebd Seances Acad Sci       Date:  1963-09-09

3.  Adriamycin: energy metabolism and mitochondrial oxidations in the heart of treated rabbits.

Authors:  M E Ferrero; E Ferrero; G Gaja; A Bernelli-Zazzera
Journal:  Biochem Pharmacol       Date:  1976-01-15       Impact factor: 5.858

4.  Rubidomycin. A new agent active in the treatment of acute lymphoblastic leukaemia.

Authors:  C Jacquillat; M Boiron; M Weil; J Tanzer; Y Najean; J Bernard
Journal:  Lancet       Date:  1966-07-02       Impact factor: 79.321

5.  Daunorubicin metabolism in acute myelocytic leukemia.

Authors:  D H Huffman; N R Bachur
Journal:  Blood       Date:  1972-05       Impact factor: 22.113

6.  Daunorubicin in the therapy of acute granulocytic leukemia.

Authors:  M Weil; O J Glidewell; C Jacquillat; R Levy; A A Serpick; P H Wiernik; J Cuttner; B Hoogstraten; L Wasserman; R R Ellison; S Gailani; K Brunner; R T Silver; V B Rege; M R Cooper; L Lowenstein; N I Nissen; F Haurani; J Blom; M Boiron; J Bernard; J F Holland
Journal:  Cancer Res       Date:  1973-05       Impact factor: 12.701

7.  An anthracycline antibiotic-induced cardiomyopathy in rabbits.

Authors:  R S Jaenke
Journal:  Lab Invest       Date:  1974-03       Impact factor: 5.662

8.  Daunomycin and adriamycin metabolism via reductive glycosidic cleavage.

Authors:  M A Asbell; E Schwartzbach; F J Bullock; D W Yesair
Journal:  J Pharmacol Exp Ther       Date:  1972-07       Impact factor: 4.030

9.  Tissue distribution and disposition of daunomycin (NCS-82151) in mice: fluorometric and isotopic methods.

Authors:  N R Bachur; A L Moore; J G Bernstein; A Liu
Journal:  Cancer Chemother Rep       Date:  1970-04

10.  Inhibition of coenzyme Q10-enzymes, succinoxidase and NADH-oxidase, by adriamycin and other quinones having antitumor activity.

Authors:  Y Iwamoto; I L Hansen; T H Porter; K Folkers
Journal:  Biochem Biophys Res Commun       Date:  1974-06-04       Impact factor: 3.575
View more
  2 in total

1.  Comparison of daunorubicin and daunorubicin-DNA complex in the treatment of acute nonlymphoblastic leukemia.

Authors:  C Paul; M Björkholm; I Christenson; L Engstedt; G Gahrton; R Hast; G Holm; A Killander; B Lantz; D Lockner; B Lönnqvist; H Mellstedt; J Palmblad; C Peterson; B Simonsson; A M Stalfelt; A M Udén; B Wadman; G Oberg
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

2.  Comparative toxicity of detorubicin and doxorubicin, free and DNA-bound, for hemopoietic stem cells.

Authors:  M Huybrechts; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.